US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SPYRE THERAPEUTICS INC

13.75

+0.17501.29%

Volume:291.39K

Turnover:3.92M

Market Cap:828.49M

PE:-4.32

High:13.80

Open:13.22

Low:13.06

Close:13.57

Loading ...

Overview Company News Filings

Spyre Therapeutics Inc - Prices Public Offering of 7,275,000 Shares at $27.50 per Share

THOMSON REUTERS

Spyre Therapeutics Inc Shares Down 1.2% in Late Trade at $28.33 Following Filing for Stock Offering

THOMSON REUTERS

Spyre Therapeutics Launching Public Offering of Shares, Warrants

MT Newswires Live

Spyre Therapeutics Announces Proposed Public Offering of Its Common Stock and Pre-Funded Warrants

THOMSON REUTERS

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Inc - Material Weakness in Internal Control Over Financial Reporting Identified

THOMSON REUTERS

Spyre Therapeutics Inc - Financial Statements for 2023 and Quarterly, Year-to-Date Periods Ended March 31, 2024 Should Not Be Relied Upon

THOMSON REUTERS

Stifel Nicolaus Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

BTIG Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc : Wedbush Raises Target Price to $65 From $45

THOMSON REUTERS

BRIEF-Spyre Therapeutics Inc - SPY001 Well Tolerated With Favorable Safety Profile

Stock Track | Spyre Therapeutics Soars on Promising Phase 1 Results for IBD Drug Candidate SPY001

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

TD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

Spyre Therapeutics Q3 EPS $(1.36) Misses $(0.83) Estimate

Spyre Therapeutics Inc: Expected Runway Well Into 2027

THOMSON REUTERS

Spyre Therapeutics Announces Grants of Inducement Awards

Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SYRE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":13.745,"timestamp":1745350523753,"preClose":13.57,"halted":0,"volume":291394,"delay":0,"floatShares":46620090,"shares":60275561,"eps":-3.180151,"marketStatus":"Trading","change":0.175,"latestTime":"04-22 15:35:34 EDT","open":13.22,"high":13.8,"low":13.06,"amount":3917928.9937859997,"amplitude":0.054532,"askPrice":13.76,"askSize":64,"bidPrice":13.72,"bidSize":110,"shortable":3,"etf":0,"ttmEps":-3.180151,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745352000000},"marketStatusCode":2,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":13.57,"preHourTrading":{"tag":"盘前","latestPrice":13.9,"preClose":13.57,"latestTime":"09:29 EDT","volume":575,"amount":7677.510975,"timestamp":1745328586041},"postHourTrading":{"tag":"盘后","latestPrice":13.57,"preClose":13.57,"latestTime":"17:50 EDT","volume":10452,"amount":141834.36,"timestamp":1745272216433},"volumeRatio":0.43287,"impliedVol":1.2821,"impliedVolPercentile":0.876},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":46620090,"roa":"-27.43%","roe":"-59.28%","lyrEps":-3.180151,"volumeRatio":0.43287,"shares":60275561,"dividePrice":0,"high":13.8,"amplitude":0.054532,"preClose":13.57,"low":13.06,"week52Low":10.91,"pbRate":"2.29","week52High":40.49,"institutionHeld":0,"latestPrice":13.745,"committee":0.264368,"eps":-3.180151,"divideRate":0,"volume":291394,"delay":0,"ttmEps":-3.180151,"open":13.22,"prevYearClose":23.28,"prevWeekClose":12.67,"prevMonthClose":16.135,"prevQuarterClose":16.135,"fiveDayClose":13.02,"twentyDayClose":19.02,"sixtyDayClose":21.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2484085955","title":"Spyre Therapeutics Inc - Prices Public Offering of 7,275,000 Shares at $27.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2484085955","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484085955?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:19","pubTimestamp":1731982748,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUABZSCV4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2484498745","title":"Spyre Therapeutics Inc Shares Down 1.2% in Late Trade at $28.33 Following Filing for Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2484498745","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484498745?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:20","pubTimestamp":1731968457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL1N3MP11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2484984153","title":"Spyre Therapeutics Launching Public Offering of Shares, Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2484984153","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484984153?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:45","pubTimestamp":1731966313,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) said Monday it started an underwritten public offering of up to $200 million of shares or pre-funded warrants.Underwriters will be given an option for a 30-day period to buy ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SYRE","BK4139"],"gpt_icon":0},{"id":"2484398914","title":"Spyre Therapeutics Announces Proposed Public Offering of Its Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2484398914","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484398914?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:14","pubTimestamp":1731964443,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA6FDXJC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2484816679","title":"Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2484816679","media":"PR Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484816679?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:14","pubTimestamp":1731964440,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ --Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease , today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30.0 million of shares of common stock at the public offering price, less the underwriting discount. All of the shares of common stock and pre-funded warrants in the offering will be sold by Spyre.This press release shall not constitute an offer to sell","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-proposed-public-211400921.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-proposed-public-211400921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","LENZ","SYRE","BK4139"],"gpt_icon":1},{"id":"2484989372","title":"Spyre Therapeutics Inc - Material Weakness in Internal Control Over Financial Reporting Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2484989372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484989372?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP0WI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2484893749","title":"Spyre Therapeutics Inc - Financial Statements for 2023 and Quarterly, Year-to-Date Periods Ended March 31, 2024 Should Not Be Relied Upon","url":"https://stock-news.laohu8.com/highlight/detail?id=2484893749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484893749?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP0WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2483934848","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483934848","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483934848?lang=en_us&edition=fundamental","pubTime":"2024-11-14 10:05","pubTimestamp":1731549905,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) yesterday and set a price target o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","SYRE"],"gpt_icon":0},{"id":"2483407425","title":"BTIG Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483407425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483407425?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:28","pubTimestamp":1731493708,"startTime":"0","endTime":"0","summary":"In a report released today, Julian Harrison from BTIG maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report), with a price target o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-spyre-therapeutics-syre-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-spyre-therapeutics-syre-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE"],"gpt_icon":0},{"id":"2482088718","title":"Spyre Therapeutics Inc : Wedbush  Raises Target Price to $65 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2482088718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482088718?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:23","pubTimestamp":1731421380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ1CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2482701791","title":"BRIEF-Spyre Therapeutics Inc - SPY001 Well Tolerated With Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2482701791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482701791?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:17","pubTimestamp":1731417458,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - Spyre Therapeutics Inc   :   * SPYRE THERAPEUTICS INC - SPY001 WELL TOLERATED WITH FAVORABLE SAFETY PROFILE   * SPYRE THERAPEUTICS INC - ANNOUNCES POSITIVE INTERIM RESULTS FOR SPY001Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"1158679239","title":"Stock Track | Spyre Therapeutics Soars on Promising Phase 1 Results for IBD Drug Candidate SPY001","url":"https://stock-news.laohu8.com/highlight/detail?id=1158679239","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158679239?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:54","pubTimestamp":1731416068,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc.  saw its stock soar by 6.53% in pre-market trading on November 12, 2024, following the release of positive interim results from the Phase 1 trial of its investigational drug SPY001, a novel half-life extended anti-α4β7 antibody for the treatment of inflammatory bowel disease .The PK data revealed a remarkable half-life of over 90 days for SPY001, approximately four times longer than vedolizumab, the currently approved anti-α4β7 antibody. This extended half-life supports t","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Spyre Therapeutics Soars on Promising Phase 1 Results for IBD Drug Candidate SPY001","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SYRE"],"gpt_icon":0},{"id":"2482706748","title":"Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2482706748","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482706748?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:30","pubTimestamp":1731414600,"startTime":"0","endTime":"0","summary":"SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class. SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab,supporting potential Q6M maintenance dosing with a single subcutaneous  injection. Planned Phase 2 induction regimen targets drug concentrations in quartile 4 of vedolizumab's exposure-response relationship, which has the potential to increase or accelerate efficacy. Single, lowest dose of SPY001 led to complete saturation of α4β7 receptors through Week 12 . Company plans to initiate a platform Phase 2 trial in mid-2025 that will include SPY001, followed by SPY002 , SPY003 , and combinations thereof, providing three optimized monotherapy readouts and three potentially paradigm-changing combination readouts under an efficient single master protocol. Management will host a webcast and conference call today at 8:00 a.m. ET. \"These interim data exceeded our expectations for SPY001 and support its potenti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-positive-interim-123000239.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-positive-interim-123000239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","BK4139","LENZ","SYRE"],"gpt_icon":0},{"id":"2482350765","title":"Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482350765","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482350765?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease , today announced it will report interim results from the Phase 1 SPY001 healthy volunteer trial on Tuesday, November 12, 2024. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation of inflammatory bowel disease  products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-host-conference-call-210500802.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-host-conference-call-210500802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","IBD","BK4181","BK4218","SYRE","BK4588","BK4585","BK4139","HST"],"gpt_icon":0},{"id":"2481159191","title":"TD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481159191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481159191?lang=en_us&edition=fundamental","pubTime":"2024-11-08 11:45","pubTimestamp":1731037532,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report). The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-spyre-therapeutics-syre-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-spyre-therapeutics-syre-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","COWN","TD"],"gpt_icon":0},{"id":"2481515001","title":"Spyre Therapeutics Q3 EPS $(1.36) Misses $(0.83) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481515001","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481515001?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:58","pubTimestamp":1731016693,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(0.83) by 63.86 percent. This is a 85.44 percent increase over losses of $(9.34) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41826913/spyre-therapeutics-q3-eps-1-36-misses-0-83-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2481216357","title":"Spyre Therapeutics Inc: Expected Runway Well Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2481216357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481216357?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA1BJDRP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2480785090","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2480785090","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480785090?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:44","pubTimestamp":1730493840,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 90,000 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on November 1, 2024 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  products by combining best-in-class antibody engineering","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-204400253.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-204400253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SYRE","LENZ","IBD"],"gpt_icon":1},{"id":"2476442975","title":"Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2476442975","media":"GuruFocus.com","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476442975?lang=en_us&edition=fundamental","pubTime":"2024-10-18 13:01","pubTimestamp":1729227690,"startTime":"0","endTime":"0","summary":"On October 9, 2024, Fairmount Funds Management LLC  made a significant new investment in the biotechnology sector by purchasing 6,620,311 shares of Inhibikase Therapeutics Inc . This transaction, executed at a price of $1.26 per share, marks a new holding for the firm and reflects a substantial commitment, as these shares now constitute 0.93% of their portfolio and 9.90% of the company's outstanding shares.GuruFocus has detected 2 Warning Signs with IKT.Established with a strategic focus on long-term value creation, Fairmount Funds Management LLC  is a prominent investment firm based in Philadelphia. The firm manages a diversified portfolio with a keen interest in the healthcare sector, among others. With assets under management totaling approximately $885 million and 13 major holdings, the firm is known for its analytical approach to investment, focusing on sustainable growth and market resilience. Their top holdings include notable names like Spyre Therapeutics Inc  and Axsome Therap","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YcHxcH4Eg319ATGzmjR7pg--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/ef71747c18e98bcce76039d590280ef7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YcHxcH4Eg319ATGzmjR7pg--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/ef71747c18e98bcce76039d590280ef7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fairmount-funds-management-llc-acquires-050130757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","QLD","QID","LENZ","TQQQ","SQQQ","SYRE","MNQmain",".IXIC","AXSM","NQmain","BK4139","BK4585","BK4505","PSQ","IKT"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":59,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36},{"market":"US","date":"2024-08-07","symbol":"SYRE","fiscalQuarterEnding":"2024/06","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.86},{"market":"US","date":"2024-05-09","symbol":"SYRE","fiscalQuarterEnding":"2024/03","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.2},{"market":"US","date":"2024-02-29","symbol":"SYRE","fiscalQuarterEnding":"2023/12","expectedEps":-0.48,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1709182800000,"reportTimeType":"post","actualEps":-2.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.25,"hold":0.0833,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":12,"updateTime":1744344000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2025-04-21","current":-3.671275,"percent":0.730887,"low":-10.261647,"twenty":-7.388883,"median":-4.914884,"eighty":-3.420672,"high":-0.199399,"avg":-5.209367,"sd":2.05872,"marketCap":763691357},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-3.765942,"twenty":-4.092735,"median":-3.38639,"eighty":-2.608303,"marketCap":1371650246},{"date":"2024-06-07","current":-4.825529,"twenty":-4.146052,"median":-3.527045,"eighty":-2.61809,"marketCap":1757578310},{"date":"2024-06-14","current":-4.511821,"twenty":-4.180278,"median":-3.580903,"eighty":-2.629835,"marketCap":1643317946},{"date":"2024-06-21","current":-3.573485,"twenty":-4.180278,"median":-3.584639,"eighty":-2.648431,"marketCap":1301552501},{"date":"2024-06-28","current":-3.166361,"twenty":-4.18028,"median":-3.584639,"eighty":-2.659197,"marketCap":1153267940},{"date":"2024-07-05","current":-3.59161,"twenty":-4.180278,"median":-3.582547,"eighty":-2.666048,"marketCap":1308154211},{"date":"2024-07-12","current":-3.922049,"twenty":-4.1738,"median":-3.59161,"eighty":-2.678038,"marketCap":1428508461},{"date":"2024-07-15","current":-4.13816,"twenty":-4.171641,"median":-3.593701,"eighty":-2.681708,"marketCap":1507221157},{"date":"2024-08-02","current":-3.753344,"twenty":-4.169482,"median":-3.595793,"eighty":-2.685378,"marketCap":1367061777},{"date":"2024-08-09","current":-6.895906,"twenty":-4.180278,"median":-3.619566,"eighty":-2.707399,"marketCap":1282507443},{"date":"2024-08-16","current":-7.250942,"twenty":-4.233229,"median":-3.6476,"eighty":-2.720856,"marketCap":1348537529},{"date":"2024-08-23","current":-6.762084,"twenty":-4.253955,"median":-3.674487,"eighty":-2.748383,"marketCap":1257619180},{"date":"2024-08-30","current":-7.666062,"twenty":-4.345056,"median":-3.707046,"eighty":-2.757559,"marketCap":1425741938},{"date":"2024-09-06","current":-7.657869,"twenty":-4.411655,"median":-3.73151,"eighty":-2.757559,"marketCap":1424218166},{"date":"2024-09-13","current":-7.786586,"twenty":-4.705472,"median":-3.759643,"eighty":-2.757559,"marketCap":1448156979},{"date":"2024-09-20","current":-8.323214,"twenty":-4.847589,"median":-3.822655,"eighty":-2.759516,"marketCap":1547959640},{"date":"2024-09-27","current":-7.956335,"twenty":-5.135333,"median":-3.898142,"eighty":-2.824601,"marketCap":1479727208},{"date":"2024-10-04","current":-7.76742,"twenty":-6.713509,"median":-3.922049,"eighty":-2.854452,"marketCap":1444592598},{"date":"2024-10-11","current":-7.452562,"twenty":-6.898091,"median":-3.929227,"eighty":-2.87941,"marketCap":1386034914},{"date":"2024-10-18","current":-8.969358,"twenty":-7.252035,"median":-3.990015,"eighty":-2.895559,"marketCap":1668130191},{"date":"2024-10-25","current":-9.226721,"twenty":-7.3874,"median":-4.004712,"eighty":-2.923697,"marketCap":1715994732},{"date":"2024-10-31","current":-9.352664,"twenty":-7.525937,"median":-4.015348,"eighty":-2.933729,"marketCap":1739417806},{"date":"2024-11-08","current":-8.930417,"twenty":-7.599425,"median":-4.026871,"eighty":-2.936176,"marketCap":1919164435},{"date":"2024-11-15","current":-7.483663,"twenty":-7.650222,"median":-4.048996,"eighty":-2.944985,"marketCap":1608254249},{"date":"2024-11-22","current":-7.375771,"twenty":-7.638736,"median":-4.07743,"eighty":-3.008113,"marketCap":1585067940},{"date":"2024-11-29","current":-7.766414,"twenty":-7.641472,"median":-4.091807,"eighty":-3.046772,"marketCap":1669017834},{"date":"2024-12-06","current":-6.979665,"twenty":-7.646653,"median":-4.11994,"eighty":-3.06708,"marketCap":1499943921},{"date":"2024-12-13","current":-6.534387,"twenty":-7.641035,"median":-4.14553,"eighty":-3.107208,"marketCap":1404252782},{"date":"2024-12-20","current":-6.318577,"twenty":-7.622349,"median":-4.17488,"eighty":-3.133634,"marketCap":1357874868},{"date":"2024-12-27","current":-6.575363,"twenty":-7.605285,"median":-4.180282,"eighty":-3.151985,"marketCap":1413058715},{"date":"2025-01-03","current":-6.515264,"twenty":-7.602508,"median":-4.208519,"eighty":-3.16373,"marketCap":1400143347},{"date":"2025-01-10","current":-6.561704,"twenty":-7.598137,"median":-4.247699,"eighty":-3.165835,"marketCap":1410123404},{"date":"2025-01-17","current":-5.613781,"twenty":-7.595453,"median":-4.253955,"eighty":-3.16915,"marketCap":1206412821},{"date":"2025-01-24","current":-5.957984,"twenty":-7.590053,"median":-4.295985,"eighty":-3.182143,"marketCap":1280382658},{"date":"2025-01-31","current":-6.083645,"twenty":-7.581791,"median":-4.354133,"eighty":-3.191991,"marketCap":1307387519},{"date":"2025-02-07","current":-6.517996,"twenty":-7.571599,"median":-4.396289,"eighty":-3.243978,"marketCap":1400730409},{"date":"2025-02-14","current":-6.195648,"twenty":-7.5588,"median":-4.51381,"eighty":-3.285739,"marketCap":1331457069},{"date":"2025-02-21","current":-6.12189,"twenty":-7.543691,"median":-4.721977,"eighty":-3.295858,"marketCap":1315606390},{"date":"2025-02-28","current":-5.184327,"twenty":-7.527033,"median":-4.825529,"eighty":-3.30956,"marketCap":1078433261},{"date":"2025-03-07","current":-5.940106,"twenty":-7.521557,"median":-4.885482,"eighty":-3.331336,"marketCap":1235649000},{"date":"2025-03-14","current":-5.224396,"twenty":-7.515906,"median":-5.129477,"eighty":-3.352623,"marketCap":1086768364},{"date":"2025-03-21","current":-5.259167,"twenty":-7.500881,"median":-5.171542,"eighty":-3.359964,"marketCap":1094001432},{"date":"2025-03-28","current":-5.125877,"twenty":-7.471223,"median":-5.184327,"eighty":-3.369262,"marketCap":1066274674},{"date":"2025-04-04","current":-4.052513,"twenty":-7.451349,"median":-5.158757,"eighty":-3.380517,"marketCap":842995751},{"date":"2025-04-11","current":-3.456852,"twenty":-7.428767,"median":-5.125877,"eighty":-3.399507,"marketCap":719087442},{"date":"2025-04-17","current":-3.598835,"twenty":-7.393254,"median":-4.931737,"eighty":-3.419927,"marketCap":748622467},{"date":"2025-04-21","current":-3.671275,"twenty":-7.388883,"median":-4.914884,"eighty":-3.420672,"marketCap":763691357}],"updateTime":1745345138166}}}